1) Leadership Transition and Strategy - Jesse Geiger, President, is stepping down after 18.5 years with the company. - CEO August Troendle emphasized the company's focus on expanding the pipeline of opportunities and improving win rates despite rising cancellations. - Medpace continues to prioritize its strategy of serving smaller biotech firms over large pharmaceutical companies, maintaining a commitment to its core business model.

2) Financial Performance and Segment Results - Q1 2026 revenue reached $706.6 million, a 26.5% YoY increase. - Net new business awards increased 23.7% YoY to $618.4 million, resulting in a net book-to-bill ratio of 0.88. - Ending backlog was approximately $2.9 billion, up 2.9% YoY, with an expected $1.94 billion to convert to revenue in the next 12 months. - EBITDA for the quarter was $149.4 million, reflecting a 25.9% YoY increase and an EBITDA margin of 21.1%.

3) Challenges and Cancellations - Cancellations reached their highest point in over a year, impacting the book-to-bill ratio. - Cancellations were primarily attributed to project-specific issues rather than macroeconomic factors, with oncology and cardiovascular areas being the most affected. - The company noted that while cancellations have increased, the quality of RFPs remains strong, indicating potential for future opportunities.

4) Operational Plans and Guidance - Medpace is focused on initiatives to improve win rates and expand its pipeline, with hopes for improvements in the coming quarters. - The company has reaffirmed its 2026 guidance for revenue, EBITDA, net income, and EPS, despite the challenges posed by cancellations. - There are no share repurchases planned in the current guidance, and cash flow from operations was reported at $151.8 million.

5) Outlook and Investor Considerations - The company is navigating a challenging environment with rising cancellations and a declining backlog coverage beyond one year, raising concerns about future revenue growth. - While the leadership transition may raise questions, the management team remains confident in Medpace's strategic direction and operational capabilities. - The transcript lacks specific details on the impact of AI investments and their potential benefits to the business, which could be a significant factor moving forward.

Bottom line: Medpace is experiencing strong revenue growth and a solid backlog, but rising cancellations and a declining backlog coverage present challenges that could impact future performance. Investors should monitor the company's ability to improve win rates and manage cancellations while navigating leadership changes.